放化疗对儿童H3K27M突变型弥漫内生型脑桥胶质瘤的疗效:基于单中心与SEER数据
本研究分析单中心44例与SEER数据库39例儿童H3K27M突变型DIPG患者,比较单纯放疗与联合替莫唑胺化疗的疗效。单中心队列中三组间ORR、DCR、PFS及OS均无显著差异;SEER队列中两组OS及DSS亦无显著差异。Stupp方案组白细胞减少及肝功能损害发生率显著高于单纯放疗组。
要点
- 加用替莫唑胺(同步/辅助或序贯)未显著改善H3K27M突变型DIPG的PFS或OS。
- Stupp方案组白细胞减少和肝功能损害发生率显著高于单纯放疗组。
- 序贯替莫唑胺组不良事件与单纯放疗组无显著差异。
核心结论
- 在H3K27M突变型DIPG患者中,放疗联合替莫唑胺无论采用同步/辅助还是序贯方式,均未显著改善无进展生存期或总生存期。
- Stupp方案显著增加血液学及肝脏毒性。
研究设计与样本
- 回顾性分析两个队列:单中心队列44例,分为单纯放疗组(n=16)、Stupp方案组(n=15)和放疗后序贯替莫唑胺组(n=13)。
- SEER数据库队列39例,分为单纯放疗组(n=19)和放化疗组(n=20)。
- 采用Kaplan-Meier法、log-rank检验和Cox回归分析生存。
主要发现
- 单中心队列中,三组客观缓解率(P=0.693)、疾病控制率(P=1.000)、中位无进展生存期(分别为6、7、8个月,P=0.621)和中位总生存期(分别为11、13、13个月,P=0.534)均无显著差异。
- Stupp组白细胞减少和肝功能损害发生率显著高于单纯放疗组(P<0.05),且≥3级不良事件有增多趋势。
- 序贯替莫唑胺组与单纯放疗组不良事件无显著差异。
- SEER队列中,两组中位总生存期均为11个月(P=0.582);中位疾病特异性生存期分别为11和12个月(P=0.585)。
临床怎么用
- 对于H3K27M突变型DIPG患儿,放疗联合替莫唑胺未能显示生存获益,且Stupp方案毒性增加,临床决策需权衡风险与获益。
局限性
- 本研究为回顾性分析,样本量较小,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brainstem tumor with a median overall survival (OS) of less than one year. Radiotherapy (RT) is the standard treatment, but the survival benefit of adding temozolomide (TMZ) remains controversial. METHODS: Two retrospective cohorts were analyzed. In the single-center cohort (44 patients), patients were divided into three groups: RT alone (n = 16), Stupp regimen (concurrent and adjuvant TMZ, n = 15), and RT followed by sequential TMZ (RT→TMZ, n = 13). In the SEER database cohort (39 patients), patients were divided into RT alone (n = 19) and chemoradiotherapy (CRT, n = 20). Survival was analyzed using the Kaplan-Meier method, log-rank test, and Cox regression. RESULTS: In the single-center cohort, no significant differences were observed among the three groups in objective response rate (ORR; P = 0.693), disease control rate (DCR; P = 1.000), median progression-free survival (PFS; 6, 7, and 8 months, respectively; P = 0.621), or median OS (11, 13, and 13 months, respectively; P = 0.534). The Stupp group had significantly higher rates of leukopenia and liver function impairment than the RT group (P < 0.05), with a trend toward more grade ≥ 3 adverse events (AEs). No significant difference in AEs was seen between RT→TMZ and RT. In the SEER cohort, median OS was 11 months in both groups (P = 0.582); median disease-specific survival (DSS) was 11 and 12 months, respectively (P = 0.585). CONCLUSION: Adding TMZ to RT whether (concurrent/adjuvant or sequential) does not significantly improve PFS or OS in H3K27M-mutant DIPG patients. The Stupp regimen significantly increases hematological and hepatic toxicity.
引用
- Wang D, Liu X, Wang J, et al. Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data. J Neurooncol. 2026. PMID: 42218248. doi:10.1007/s11060-026-05622-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。